Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSJVX3)

• Drug Name: CM3.1-AC100 Drug Info
• Synonyms: CM-3, CellMed/AstraZeneca; GLP-1 analog (diabetes), CellMed/AstraZeneca

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMSJVX3

Molecule-Related Drug Atlas

Drug(s) Targeting Glucagon-like peptide 1 receptor (GLP1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Semaglutide	DMAGFOD	Type-2 diabetes	5A11	Approved	[2]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[3]
Exenatide	DMYHBKN	Inflammation	1A00-CA43.1	Approved	[4]
Dulaglutide	DMYXBV3	Type-2 diabetes	5A11	Approved	[5]
Lixisenatide	DM0QJDC	Type-2 diabetes	5A11	Approved	[6]
Pramlintide	DM0EZ9Q	Type-1/2 diabetes	5A10-5A11	Approved	[3]
Albiglutide	DM1JEGF	Type-2 diabetes	5A11	Approved	[6]
Tirzepatide	DMQNMAT	Type 2 diabetes	5A11	Approved	[7]
Efpeglenatide	DMKA2PI	Type-2 diabetes	5A11	Phase 3	[8]
GLP-1	DMR6YH3	Diabetic complication	5A2Y	Phase 3	[2]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT01165502) Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers. U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
• [3] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [4] Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
• [5] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [6] GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
• [7] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)